EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSMZEG00005008656
Gene Symbol: KCNQ2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSMZEG00005020367
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSMZEG00005027348
Gene Symbol: KCNQ5
3 Cross references
196 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSMZEG00005012184
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:

Presenilin-1

Ensembl ID : ENSMZEG00005011306
Gene Symbol: LOC101485940
3 Cross references
200 Possible Orthologues:

Presenilin-2

Ensembl ID : ENSMZEG00005015288
Gene Symbol: LOC101475262
3 Cross references
205 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme

Ensembl ID : ENSMZEG00005008666
Gene Symbol: LOC101476241
2 Cross references
403 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSMZEG00005006242
Gene Symbol: LOC101473181
4 Cross references
255 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSMZEG00005000572
Gene Symbol: LOC101481782
3 Cross references
250 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSMZEG00005024067
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSMZEG00005005526
Gene Symbol: PTGDR2
4 Cross references
135 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSMZEG00005010895
Gene Symbol: PTGDR2
3 Cross references
145 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).